High Throughput Screening Identifies a Novel Compound Protecting Cardiomyocytes from Doxorubicin-Induced Damage

Figure 6

EODB does not interfere with the antitumor effect of DOX. A549 (a, c), SAOS-2 (b, d), Jurkat (e) and THP-1 (f) cells were pretreated with EODB (12 μM) for 30 min and were then incubated with DOX for 24 h (a, b, e, and f) or for 5 days (c and d). Viability (a, b, e and f) and proliferation (c, d) were determined with MTT assay and sulforhodamine B assay, respectively. Mean ± SEM of 3 independent experiments is presented. ().

(a)

(b)

(c)

(d)

(e)

(f)